With the breastcancer 1b results now public dynamics re options may have changed, causing a dilemma for some of us that hold.
That is to say:
The unprecedented ORR (100%) and the publicly known fact that only one more CR is needed from the 11 recruits to forward an additional 15 recruits of the phase 2 may or may not result in an early partnering.
Following this, the highly promising AML results were last announced to be scheduled for public knowledge as early as June this year.
The point then is, for those that have allocated funds in case the options become exercisable, does one use those funds at current entry or between now and expiry date of June 30th.
The upcoming quarter may shed light to the progress of the release of the AML results.
Disclosure: food for thought only and definitely not ment as finance or influential advise (IMO).
Exciting times ahead for ptx indeed.
PTX Price at posting:
11.5¢ Sentiment: Buy Disclosure: Held
